Previous Article | Next Article 
Journal of Clinical Microbiology, November 2001, p. 3915-3919, Vol. 39, No. 11
Department of Clinical Microbiology and
Immunology1 and Outpatient Sexually
Transmitted Disease Clinic, Department of
Dermatovenereology,2 Örebro Medical Centre
Hospital, SE-70185 Örebro, Department of Clinical
Microbiology, Malmö University Hospital, SE-20502
Malmö,3 and Division of Virology,
Department of Microbiology, Pathology and Immunology, Karolinska
Institutet, Huddinge University Hospital, SE-14186
Huddinge/Stockholm,4 Sweden
Received 16 April 2001/Returned for modification 15 June
2001/Accepted 12 August 2001
A method for detection and genotyping of genital Chlamydia
trachomatis infections based on omp1 gene
amplification and sequencing was developed. DNA was extracted from
urogenital or urine samples using a Chelex-based method, and an
approximately 1,100-bp-long fragment from the omp1 gene
was directly amplified and sequenced. Genotyping was performed by BLAST
similarity search, and phylogenetic tree analysis was used to
illustrate the evolutionary relationships between clinical isolates and
reference strains. The method was used to determine the genotypes of
C. trachomatis in 237 positive urogenital and/or urine
specimens collected at a Swedish sexually transmitted disease clinic
during 1 year. The most common genotypes corresponded to serotypes E
(47%) and F (17%). The omp1 gene was highly conserved
for genotype E (106 of 112 samples without any mutation) and F (41 of
42 samples without any mutation) strains but appear slightly less
conserved for genotypes G (n = 6) and H
(n = 6), where the sequences displayed one to four
nucleotide substitutions relative to the reference sequence. Genotyping
of samples collected at the follow-up visit indicated that two patients had become reinfected, while three other patients suffered treatment failure or reinfection. One woman appeared to have a mixed infection with two different C. trachomatis strains. This
omp1 genotyping method had a high reproducibility and
could be used for epidemiological characterization of sexually
transmitted Chlamydia infections.
Sexually transmitted
infection with Chlamydia trachomatis is a common treatable
urogenital infection in young adults worldwide and is associated with a
spectrum of clinical diseases, including urethritis and epididymitis
among men and cervicitis, salpingitis, and pelvic inflammatory disease
among women (4, 10, 21). In Sweden, reporting gonorrhea
and syphilis has been mandatory under the Communicable Diseases Act
since 1919, and reporting genital infection with C. trachomatis has been mandatory since April 1988. The incidence of
genital chlamydial infections declined in all Swedish counties until
1996. It has been suggested that this decline was due to contact
tracing, screening, and treatment of asymptomatic men and women
(10), but data from the Swedish Institute for Infectious
Disease Control show that genital infections with C. trachomatis are now again increasing. The incidence was 172 cases
per 100,000 inhabitants in 1998 and 217 cases per 100,000 inhabitants
in 2000 (27).
Characterization of C. trachomatis strains can provide
valuable information about the variants circulating in the community, and with better knowledge of the epidemiology of Chlamydia
infection, efforts against spread can probably be more effective.
Serotyping with monoclonal antibodies recognizing antigenic
determinants located on the major outer membrane protein (MOMP) is
the reference method for typing C. trachomatis isolates
(12, 29, 30). The MOMP is the immunodominant antigen of
C. trachomatis and contains four variable domains (VDI to
VDIV) that are flanked and interspaced by five constant domains
(30). In order to study the epidemiology of C. trachomatis infections, new methods The aim of the present study was to establish a PCR method for genetic
characterization of clinical C. trachomatis isolates in a
Swedish population by sequence analysis of the omp1 gene.
Clinical samples and strains.
Urogenital and/or urine
samples for diagnosis of C. trachomatis were prospectively
obtained from all new attendees (n = 2,195) of the
Outpatient Sexually Transmitted Disease (STD) Clinic, Örebro Medical Centre Hospital, Örebro, Sweden, during 1 year (1 March 1999 to 29 February 2000). The mean age for men (n = 1,141) was 28.5 (range, 14 to 68) years, and the mean age for women
(n = 1,054) was 25.7 (range, 13 to 59) years.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.11.3915-3919.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Characterization of Chlamydia trachomatis
omp1 Genotypes among Sexually Transmitted Disease Patients
in Sweden
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
such as PCR, restriction fragment length polymorphism, and sequencing of the omp1
gene, which encodes the MOMP proteinhave recently been described
(7, 9, 11, 12, 17, 20, 23, 25).
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
70°C until processed
for tissue culture. At the same examination, first-void urine samples
(5 to 10 ml) from both men and women were collected and stored at 2 to
8°C in a sterile screw-cap plastic tube. The first 779 urine samples
were tested by the Chlamydia trachomatis Amplicor PCR (Roche
Diagnostic Systems, Inc., Branchburg, N.J.), and the remaining samples
were tested by the COBAS Amplicor Chlamydia trachomatis Test
(Roche Diagnostic Systems) due to changed diagnostic screening
PCR methods during the period of the study. All C. trachomatis-positive patients were treated with appropriate
antibiotics and requested to come for a checkup visit 4 to 5 weeks
after the initial sample was obtained.
20°C until used in the study. The first choice for the omp1 PCR was the
urogenital specimen (n = 190), and the second choice
was the urine sample (n = 48), if the urogenital sample
was negative or not obtained. One C. trachomatis-negative
patient sample per every C. trachomatis-positive sample was
randomly selected each day, and these were used as negative controls in
the study. Twenty-four patients who were epidemiologically highly
suspected of having a C. trachomatis infection, but whose
diagnostic tests for C. trachomatis were negative, were also
included in the study.
The following C. trachomatis reference strains were used for
optimization of PCR and DNA sequencing: serotypes A/HAR-1/OT, B/TW-5,
Ba/AP-2/OT, C/UW-1/OT, D/ICCAL-8/ON, E/DK-20/ON, F/MRC-301/GU, G/IOL-238/R, H/UW-4/GCx, I/UW-12/GU, J/UW-36/GCx, K/UW-31/GCx, L1/440
Bu, L2/434 Bu, and L3/404 Bu, as well as Chlamydia
pneumoniae strain IOL-207 and Chlamydia psittaci strain
6BC. A C. trachomatis serotype E strain, used as a control
in the diagnostic tissue culture and PCR analyses above (provided from
Department of Microbiology, Halmstad Hospital, Halmstad,
Sweden), was used as a positive control in each PCR run. All the
reference strains were originally from the Institute of Ophthalmology,
London, United Kingdom.
Isolation of DNA. DNA was isolated directly from the clinical samples and the reference strains using Chelex 100 resin (catalog no. CA 94547; Bio-Rad Laboratories) (28). A volume of 100 µl from the clinical specimens (in 2SP medium) for tissue culture or a pellet from 1,000 µl of urine was washed in distilled water for 30 min at room temperature and microcentrifuged for 5 min at 18,000 × g. The pellet was resuspended to a final volume of 200 µl in distilled water and mixed with 2 µl of 10-mg/ml proteinase K (catalog no. P6556; Sigma) and incubated for 1 h at 37°C. The tubes were then microcentrifuged for 5 min at 18,000 × g, and the pellet was resuspended in 200 µl of 5% Chelex 100 resin, thoroughly mixed and incubated at 56°C for 30 min, mixed again, and incubated in boiling water for 8 min. The cell debris was pelleted by centrifugation at 10,000 × g for 3 min, and the supernatant containing the DNA was withdrawn and stored at 4°C until used.
omp1 PCR. The optimized omp1 PCR was carried out as follows. The DNA preparation (10 µl) was added to the PCR mixture (40 µl) containing 1.5 U of AmpliTaqGold DNA polymerase (PE Biosystems, Branchburg, N.J.), 1× PCR buffer (PE Biosystems), 2.0 mM MgCl2, a 200 µM concentration of each deoxynucleoside triphosphate (PE Biosystems), and a 1.0 µM concentration of each primer (Scandinavian Gene Synthesis AB, Köping, Sweden): primer P1 (5'-ATG AAA AAA CTC TTG AAA TCG G-3') (7) and primer OMP 2 (5'-ACT GTA ACT GCG TAT TTG TCT G-3') (designed from C. trachomatis strains sequenced in reference 25). The PCR mixture was overlaid with 50 µl of mineral oil and was run in a GeneAmp PCR System 9600 (PE Biosystems) at 94°C for 10 min followed by 40 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1.5 min. At the end of the final cycle, an extension at 72°C for 7 min was included before storage at 4°C. A positive control (DNA of C. trachomatis serotype E) and a negative reagent control (distilled water), as well as the randomly selected negative sample controls, were included in each PCR run. The amplification product, which consisted of approximately 1,100 bp from the omp1 gene, was visualized after electrophoresis through a 1.5% agarose gel containing ethidium bromide. The DNA Molecular Weight Marker VI (Boehringer Mannheim, GmbH, Mannheim, Germany) was included in each electrophoresis.
DNA sequencing. The PCR products were purified using the High Pure PCR product purification kit (Boehringer Mannheim, Indianapolis, Ind.) according to the manufacturer's instructions. Sufficient amounts of purified DNA (1 to 4 µl) were mixed with 2 µl of a 50 µM concentration of one of the primers, S1 (5'-TTG AGT TCT GCT TCC TCC T-3') or OMP 2 (5'-ACT GTA ACT GCG TAT TTG TCT G-3') (Scandinavian Gene Synthesis AB), in separate reaction mixtures and sequenced with the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction kit (PE Biosystems, Warrington, United Kingdom). The DyeEx Spin kit (catalog no. 63106; Qiagen, Hilden, Germany) was used to remove the dye terminators in the cycle sequencing reaction mixtures according to the manufacturer's instructions. The sequence of the omp1 gene was determined by using an ABI PRISM 310 Genetic Analyser (PE Biosystems). Each PCR product was sequenced twice in each direction, and this gave an overlap of about 200 bp in the middle of the omp1 gene.
BLAST and phylogenetic analyses. In a first analysis, the individual consensus sequence (about 1,100 nucleotides) of the clinical isolates was determined by comparison to omp1 nucleotide sequences of known serovars of C. trachomatis strains using the BLAST search tool at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov).
Phylogenetic tree analyses were used to illustrate the evolutionary relationships between clinical isolates and the following reference strains of C. trachomatis obtained from GenBank (accession numbers in parentheses): A/SA1/OT (M58938), Ba/AP-2 (AF063194), B/TW-5 (M33636), C/TW-3/OT (M17343), D/B-120 (X62918), D/B-185 (X62919), D/IC-CAL-8 (X62920), E/DK-20/ON (X52557), F/MRC-301/GU (X52080), G/UW57/Cx (AF063199), H/Wash (X16007), I/UW-12 (AF063200), J/UW36/Cx (AF063202), K/UW31/Cx (AF063204), L1/440 Bu (M36533), L2/434 Bu (M14738), and L3/404 Bu (X55700). MOMP sequences representing C. psittaci (AF131889), C. pneumoniae (L25436), and a murine variant of C. trachomatis (MoPn [M64171]) were used as outgroup sequences to root the tree. The sequences were manually aligned using BioEdit (version 5.0.0) software. Preliminary phylogenetic trees with all sequences were constructed using the DNADIST and NEIGHBOR programs in the PHYLIP (version 3.52c) package (6). A final tree with selected sequences was constructed using a parallelized version of DNAml (5, 6; A. Holmberg et al., unpublished data). Bootstrapping was performed using the SEQBOOT, DNADIST, NEIGHBOR, and CONSENSE programs in the PHYLIP (version 3.52c) package (6). All programs were run under Linux on a custom-built Beowulf cluster, consisting of one master and four slaves (all five were 350-MHz 586 AMD-K6 PCs).Ethics. The research ethics committee at Örebro County Council, Örebro, Sweden, approved the study.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
omp1 PCR. All tested prototype isolates of serovars A to L3 of C. trachomatis were successfully amplified in the omp1 PCR, whereas the C. pneumoniae and C. psittaci strains were PCR negative. The omp1 PCR showed high concordance with the diagnostic tests for C. trachomatis, and out of 238 C. trachomatis-positive clinical samples analyzed with the diagnostic tests, 235 were found to be positive in the omp1 PCR. Consequently, three clinical samples were found to be negative in the omp1 PCR and cell culture but positive in the Amplicor PCR. Retesting with the COBAS Amplicor test showed that two of the three samples were negative, and thus these were considered false positives in the Amplicor PCR. The remaining COBAS Amplicor-positive sample was repeatedly negative in the omp1 PCR.
Samples from 2 of the 24 C. trachomatis-exposed but -negative partners were found to be positive in the omp1 PCR. When these two samples were retested with the COBAS Amplicor test, one was positive and the other was negative. All clinical samples included in the study as negative controls (one per positive sample) were negative in the omp1 PCR.Sequence and phylogenetic analyses. Optimization of the DNA sequence analysis was performed using reference isolates for C. trachomatis serovars A, B, Ba, C, D, E, F, G, H, I, J, K, L1, L2, and L3. All isolates were successfully amplified and sequenced.
Sequence analysis of the omp1 gene from amplified DNA from the 237 clinical strains revealed that the most prevalent genotypes corresponded to C. trachomatis serovar E (47.3%), followed by F, K, D/B-120, D, J, Ia, D/B-185, G, H, and 1 strain of Ba. All nucleotide sequences were easy to read and interpret when compared by BLAST similarity search. The results are summarized in Table 1, and the evolutionary relationships between clinical isolates and reference strains are shown in Fig. 1.
|
|
G substitution at position 420, and 3 strains displayed a GA substitution at position 997 (compared to E/DK-20/ON [19]). The latter substitution resulted in
an alanine-to-threonine amino acid replacement, whereas the former was
silent. Similarly, 4 of 10 genotype J sequences displayed a silent
CT substitution at position 369 (compared to J/UW36), and 3 of 21 genotype K sequences displayed a silent CT substitution at position
132 (compared to K/UW 31/Cx).
|
|
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
In this study we have established a method for PCR amplification and sequence analysis of the omp1 gene of C. trachomatis from clinical specimens. Our omp1 PCR worked successfully with both urogenital samples and urine samples and showed no cross-reactions with C. pneumoniae or C. psittaci or other false-positive reactions. All but 1 of 238 samples that were positive by the diagnostic Chlamydia tests were positive in the omp1 PCR. One reason for this false-negative result could be that the omp1 gene is only present in one copy per organism, whereas the plasmid that is targeted by the diagnostic tests is present in approximately 10 copies per organism (13, 18, 24). However, the omp1 PCR was also positive in 2 of 24 diagnostic test negative samples from individuals epidemiologically highly suspected of having a C. trachomatis infection. One of these two samples was positive after retesting by the diagnostic test, perhaps due to the freeze-thawing, as recently described (3). The remaining sample, which was found positive in the omp1 PCR only, could contain a plasmid-free variant of C. trachomatis (1).
C. trachomatis in these Swedish clinical isolates was most frequently genotyped as E (47%) or F (17%). Also relatively prevalent were omp1 genotypes D, D/B-120, J, and K (5 to 10%), whereas the remaining genotypes (Ba, D/B-185, G, H, and Ia) were more infrequently encountered. The genotype distribution in our 237 clinical specimens was broadly similar to the serovar distributions reported previously (15, 20). There was a high level of conservation of the omp1 gene in infections caused by genotype E, of which 106 out of 112 had 100% similarity to the strain E/DK-20/ON. These findings are in agreement with those of Rodriguez et al. (22), who reported a high level of conservation of E strains from different geographic origins. However, we found minor sequence variations within the different genotypes in our clinical material. Some of these genetic variants were detected only in a single sample, which makes it difficult to exclude the possibility that they represent sequencing artifacts, but most of them were independently detected in two or more samples, which strongly indicates that they were accurate. Thus, 4 of 10 clinical genotype J strains were found to have one identical substitution, but at a different position than that described by Morré et al. (14). Similarly, five of six of genotype G sequences had identical substitutions that were different from the substitutions reported previously (14, 16), and all six genotype H sequences harbored two identical mutations. It has been speculated that such omp1 genovariants occur as a result of point mutations and recombination events selected by immune pressure (8). However, several of the nucleotide substitutions that we detected were synonymous (i.e., silent), which suggests that they were evolutionarily neutral.
The phylogenetic tree analysis of all the genotype sequences found indicates that there is no simple correlation between the disease manifestation and omp1 gene phylogeny. The omp1 sequences of genotype H, I, J, and K, which were represented in our material from patients with symptomatic or subclinical genital infections, were closely related to each other. However, they were also closely related to genotypes A and C, which are associated with trachoma, and genotype L3, which is associated with lymphogranuloma venerum. These observations are broadly the same as those reported by Stothard et al. when they compared omp1 sequences from clinical strains from the United States to sequences registered in GenBank (26). Few studies have addressed the possible correlation between specific serovars or genotypes and disease manifestations and severity of disease. However, in a recent Finnish serological study it was stated that serovar G could be associated with subsequent development of cervical squamous cell carcinoma (2). This finding is interesting and requires further study, especially due to the fact that some genotype G sequences in our study differ from the prototype sequence by three amino acids (Table 2).
Genotyping was also useful in the follow-up of the Chlamydia-infected patients, and five patients were still C. trachomatis positive at the follow-up visit. In two of these patients, the initial sample and follow-up sample showed different omp1 genotypes, which indicates that new sexual partners had reinfected these patients. In the other three patients the genotypes were identical in the initial and follow-up samples, suggesting treatment failure or reinfection with the same genotype. Furthermore, one woman was found to have a mixed infection with two genotypes of C. trachomatis, and she had had two sexual partners, each carrying one of these different genotypes.
In conclusion, we have established a sensitive and relatively simple method for the genotyping of C. trachomatis strains in clinical samples based on sequencing of the omp1 gene. Genotypes E and F dominated in our Swedish material, and the individual sequences were stable and showed limited variation. This omp1 genotyping method provided interesting results concerning double infections and reinfections and could be useful for epidemiological characterization of circulating C. trachomatis strains in the community.
| |
ACKNOWLEDGMENTS |
|---|
We thank the staff at the Outpatient Sexually Transmitted Disease Clinic and at the Department of Clinical Microbiology and Immunology for all effort and positive attitude shown during the study.
This work was supported by grants from the Örebro Medical Research Foundation, Örebro Medical Centre Hospital, and The National Institute for Public Health, Stockholm, Sweden.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Clinical Microbiology and Immunology, Örebro Medical Centre Hospital, SE-70185 Örebro, Sweden. Phone: 46-19-6021520. Fax: 46-19-127416. E-mail: margaretha.jurstrand{at}orebroll.se.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
| 1. |
An, Q.,
G. Radcliffe,
R. Vassallo,
D. Buxton,
W. J. O'Brien,
D. A. Pelletier,
W. G. Weisburg,
J. D. Klinger, and D. M. Olive.
1992.
Infection with a plasmid-free variant Chlamydia related to Chlamydia trachomatis identified by using multiple assays for nucleic acid detection.
J. Clin. Microbiol.
30:2814-2821 |
| 2. |
Antilla, T.,
P. Saikku,
P. Koskela,
A. Bloigu,
J. Dillner,
I. Ikäheimo,
E. Jellum,
M. Lehtinen,
P. Lenner,
T. Hakulinen,
A. Närvänen,
E. Pukkala,
S. Thoresen,
L. Youngman, and J. Paavonen.
2001.
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.
JAMA
285:47-51 |
| 3. | Berg, E. S., G. Ånestad, H. Moi, G. Storvold, and K. Skaug. 1997. False-negative results of a ligase chain reaction assay to detect Chlamydia trachomatis due to inhibitors in urine. Eur. J. Clin. Microbiol. Infect. Dis. 16:727-731[CrossRef][Medline]. |
| 4. | Cates, W. J., Jr., and J. N. Wassenheit. 1991. Genital chlamydial infections: epidemiology and reproductive sequelae. Am. J. Obstet. Gynecol. 164:1771-1781[Medline]. |
| 5. | Ceron, C., J. Dopazo, E. L. Zapata, J. M. Carazo, and O. Trelles. 1998. Parallel implementation for DNAml program on message-passing architectures. Parallel Comput. 24:701-716[CrossRef]. |
| 6. | Felsenstein, J. 1993. PHYLIP: phylogenetic inference package, version 3.52.c. University of Washington, Seattle. |
| 7. | Frost, E. H., S. Deslandes, S. Veilleux, and D. Bourgaux-Ramoisy. 1991. Typing Chlamydia trachomatis by detection of restriction fragment length polymorphism in the gene encoding the major outer membrane protein. J. Infect. Dis. 163:1103-1107[Medline]. |
| 8. |
Hayes, L. J.,
P. Yearsley,
J. D. Treharne,
R. A. Ballard,
G. H. Fehler, and M. E. Ward.
1994.
Evidence for naturally occurring recombination in the gene encoding the major outer membrane protein of lymphogranuloma venerum isolates of Chlamydia trachomatis.
Infect. Immun.
62:5659-5663 |
| 9. |
Kaltenboeck, B.,
K. G. Kousoulas, and J. Storz.
1992.
Two-step polymerase chain reactions and restriction endonuclease analyses detect and differentiate ompA DNA of Chlamydia spp.
J. Clin. Microbiol.
30:1098-1104 |
| 10. |
Kamwendo, F.,
L. Forslin,
L. Bodin, and D. Danielsson.
1998.
Programmes to reduce pelvic inflammatory diseasethe Swedish experience.
Lancet
351(Suppl. 3):25-28.
|
| 11. | Lampe, M. F., K. G. Wong, and W. E. Stamm. 1995. Sequence conservation in the major outer membrane protein gene among Chlamydia trachomatis strains isolated from the upper and lower urogenital tract. J. Infect. Dis. 172:589-592[Medline]. |
| 12. |
Lampe, M. F.,
R. J. Suchland, and W. E. Stamm.
1993.
Nucleotide sequence of the variable domains within the major outer membrane protein gene from serovariants of Chlamydia trachomatis.
Infect. Immun.
61:213-219 |
| 13. |
Mahony, J. B.,
K. E. Luinstra,
J. W. Sellors, and M. A. Chernesky.
1993.
Comparison of plasmid- and chromosome-based polymerase chain reaction assays for detecting Chlamydia trachomatis nucleic acids.
J. Clin. Microbiol.
31:1753-1758 |
| 14. |
Morré, S. A.,
J. M. Ossewaarde,
J. Lan,
G. J. J. van Doornum,
J. M. M. Walboomers,
D. M. MacLaren,
C. J. L. M. Meijier, and A. J. C. van den Brule.
1998.
Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis.
J. Clin. Microbiol.
36:345-351 |
| 15. |
Morré, S. A.,
R. Moesvan,
I. Valkengoed,
J. P. Boeke,
J. T. M. van Eijk,
C. J. L. Meijer, and A. J. C. van den Brule.
1998.
Genotyping of Chlamydia trachomatis in urine specimens will facilitate large epidemiological studies.
J. Clin. Microbiol.
36:3077-3078 |
| 16. |
Norum Pedersen, L.,
O. H. Kjaer,
J. Kjolseth Moller,
T. Falck Orntoft, and L. Ostergaard.
2000.
High-resolution genotyping of Chlamydia trachomatis from recurrent urogenital infections.
J. Clin. Microbiol.
38:3068-3071 |
| 17. | Ostergaard, L. 1999. Diagnosis of urogenital Chlamydia trachomatis infection by use of DNA amplification. APMIS 107(Suppl. 89):5-36. |
| 18. | Palmer, L., and S. Falkow. 1986. A common plasmid of Chlamydia trachomatis. Plasmid 16:52-62[CrossRef][Medline]. |
| 19. |
Peterson, E. M.,
B. A. Markhoff, and L. M. de la Maza.
1990.
The major outer membrane protein nucleotide sequence of Chlamydia trachomatis, serovar E.
Nucleic Acids Res.
18:3414 |
| 20. |
Poole, E., and I. Lamont.
1992.
Chlamydia trachomatis serovar differentiation by direct sequence analyses of the variable segment 4 region of the major outer membrane protein gene.
Infect. Immun.
60:1089-1094 |
| 21. |
Quinn, T C.,
C. Gaydos,
M. Shepherd,
L. Bobo,
E. W. Hook III,
R. Viscidi, and A. Rompalo.
1996.
Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships.
JAMA
276:1737-1742 |
| 22. |
Rodriguez, P.,
B. de Barbeyrac,
K. Persson,
B. Dutilh, and C. Bebear.
1993.
Evaluation of molecular typing for epidemiological study of Chlamydia trachomatis genital infections.
J. Clin. Microbiol.
31:2238-2240 |
| 23. | Sayada, C., E. Denamur, and J. Elion. 1992. Complete sequence of the major outer membrane protein-encoding gene of Chlamydia trachomatis serovar Da. Gene 120:129-130[CrossRef][Medline]. |
| 24. | Sriprakash, K. S., and E. S. Macavoy. 1987. Characterization and sequence of a plasmid from the trachoma biovar of Chlamydia trachomatis. Plasmid 18:205-214[CrossRef][Medline]. |
| 25. |
Stephens, R. S.,
R. Sanchez-Pescador,
E. A. Wagar,
C. Inouye, and M. S. Urdea.
1987.
Diversity of Chlamydia trachomatis major outer membrane protein genes.
J. Bacteriol.
169:3879-3885 |
| 26. |
Stothard, D. R.,
G. Boguslawski, and R. B. Jones.
1998.
Phylogenic analyses of the Chlamydia trachomatis major outer membrane protein and examination of potential pathogenic determinants.
Infect. Immun.
66:3618-3625 |
| 27. | Swedish Institute for Infectious Disease Control. 2000. Annual report. Swedish Institute for Infectious Disease Control, Stockholm, Sweden. |
| 28. | Walsh, S. P., D. A. Metzger, and R. Higuchi. 1991. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. BioTechniques 10:506-513[Medline]. |
| 29. | Wang, S. P., C. C. Kuo, R. C. Barnes, R. S. Stephens, and J. T. Grayson. 1985. Immunotyping of Chlamydia trachomatis with monoclonal antibodies. J. Infect. Dis. 152:791-800[Medline]. |
| 30. |
Yuan, Y.,
Y. X. Zhang,
N. G. Watkins, and H. D. Caldwell.
1989.
Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 Chlamydia trachomatis serovars.
Infect. Immun.
57:1040-1049 |
Journal of Clinical Microbiology, November 2001, p. 3915-3919, Vol. 39, No. 11
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.11.3915-3919.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Webley, W. C., Tilahun, Y., Lay, K., Patel, K., Stuart, E. S., Andrzejewski, C., Salva, P. S.
(2009). Occurrence of Chlamydia trachomatis and Chlamydia pneumoniae in paediatric respiratory infections. Eur Respir J
33: 360-367
[Abstract] [Full Text] -
Quint, K., Porras, C., Safaeian, M., Gonzalez, P., Hildesheim, A., Quint, W., van Doorn, L.-J., Silva, S., Melchers, W., Schiffman, M., Rodriguez, A. C., Wacholder, S., Freer, E., Cortes, B., Herrero, R., for the Costa Rican Vaccine Trial Group,
(2007). Evaluation of a Novel PCR-Based Assay for Detection and Identification of Chlamydia trachomatis Serovars in Cervical Specimens. J. Clin. Microbiol.
45: 3986-3991
[Abstract] [Full Text] -
Quint, K. D., van Doorn, L.-J., Kleter, B., de Koning, M. N.C., van den Munckhof, H. A.M., Morre, S. A., ter Harmsel, B., Weiderpass, E., Harbers, G., Melchers, W. J.G., Quint, W. G.V.
(2007). A Highly Sensitive, Multiplex Broad-Spectrum PCR-DNA-Enzyme Immunoassay and Reverse Hybridization Assay for Rapid Detection and Identification of Chlamydia trachomatis Serovars. J. Mol. Diagn.
9: 631-638
[Abstract] [Full Text] -
Klint, M., Fuxelius, H.-H., Goldkuhl, R. R., Skarin, H., Rutemark, C., Andersson, S. G. E., Persson, K., Herrmann, B.
(2007). High-Resolution Genotyping of Chlamydia trachomatis Strains by Multilocus Sequence Analysis. J. Clin. Microbiol.
45: 1410-1414
[Abstract] [Full Text] -
Gao, X., Chen, X.-S., Yin, Y.-P., Zhong, M.-Y., Shi, M.-Q., Wei, W.-H., Chen, Q., Peeling, R. W., Mabey, D.
(2007). Distribution Study of Chlamydia trachomatis Serovars among High-Risk Women in China Performed Using PCR-Restriction Fragment Length Polymorphism Genotyping. J. Clin. Microbiol.
45: 1185-1189
[Abstract] [Full Text] -
Stark, D., van Hal, S., Hillman, R., Harkness, J., Marriott, D.
(2007). Lymphogranuloma Venereum in Australia: Anorectal Chlamydia trachomatis Serovar L2b in Men Who Have Sex with Men. J. Clin. Microbiol.
45: 1029-1031
[Abstract] [Full Text] -
Klint, M., Lofdahl, M., Ek, C., Airell, A., Berglund, T., Herrmann, B.
(2006). Lymphogranuloma Venereum Prevalence in Sweden among Men Who Have Sex with Men and Characterization of Chlamydia trachomatis ompA Genotypes. J. Clin. Microbiol.
44: 4066-4071
[Abstract] [Full Text] -
Xiong, L., Kong, F., Zhou, H., Gilbert, G. L.
(2006). Use of PCR and Reverse Line Blot Hybridization Assay for Rapid Simultaneous Detection and Serovar Identification of Chlamydia trachomatis. J. Clin. Microbiol.
44: 1413-1418
[Abstract] [Full Text] -
Hsu, M.-C., Tsai, P.-Y., Chen, K.-T., Li, L.-H., Chiang, C.-C., Tsai, J.-J., Ke, L.-Y., Chen, H.-Y., Li, S.-Y.
(2006). Genotyping of Chlamydia trachomatis from clinical specimens in Taiwan.. J Med Microbiol
55: 301-308
[Abstract] [Full Text] -
Stevens, M. P., Tabrizi, S. N., Muller, R., Krause, V., Garland, S. M.
(2004). Characterization of Chlamydia trachomatis omp1 Genotypes Detected in Eye Swab Samples from Remote Australian Communities. J. Clin. Microbiol.
42: 2501-2507
[Abstract] [Full Text] -
Lister, N. A, Tabrizi, S. N., Fairley, C. K., Smith, A., Janssen, P. H., Garland, S.
(2004). Variability of the Chlamydia trachomatis omp1 Gene Detected in Samples from Men Tested in Male-Only Saunas in Melbourne, Australia. J. Clin. Microbiol.
42: 2596-2601
[Abstract] [Full Text] -
Millman, K., Black, C. M., Johnson, R. E., Stamm, W. E., Jones, R. B., Hook, E. W., Martin, D. H., Bolan, G., Tavare, S., Dean, D.
(2004). Population-Based Genetic and Evolutionary Analysis of Chlamydia trachomatis Urogenital Strain Variation in the United States. J. Bacteriol.
186: 2457-2465
[Abstract] [Full Text] -
Lysen, M., Osterlund, A., Rubin, C.-J., Persson, T., Persson, I., Herrmann, B.
(2004). Characterization of ompA Genotypes by Sequence Analysis of DNA from All Detected Cases of Chlamydia trachomatis Infections during 1 Year of Contact Tracing in a Swedish County. J. Clin. Microbiol.
42: 1641-1647
[Abstract] [Full Text] -
Lister, N. A., Tabrizi, S. N., Fairley, C. K., Garland, S.
(2004). Validation of Roche COBAS Amplicor Assay for Detection of Chlamydia trachomatis in Rectal and Pharyngeal Specimens by an omp1 PCR Assay. J. Clin. Microbiol.
42: 239-241
[Abstract] [Full Text] -
Ngandjio, A., Clerc, M., Fonkoua, M. C., Thonnon, J., Lunel, F., Bebear, C., Bianchi, A., de Barbeyrac, B.
(2004). Restriction endonuclease patterns of the omp1 gene of reference Chlamydia trachomatis strains and characterization of isolates from Cameroonian students. J Med Microbiol
53: 47-50
[Abstract] [Full Text] -
Ngandjio, A., Clerc, M., Fonkoua, M. C., Thonnon, J., Njock, F., Pouillot, R., Lunel, F., Bebear, C., de Barbeyrac, B., Bianchi, A.
(2003). Screening of Volunteer Students in Yaounde (Cameroon, Central Africa) for Chlamydia trachomatis Infection and Genotyping of Isolated C. trachomatis Strains. J. Clin. Microbiol.
41: 4404-4407
[Abstract] [Full Text] -
Falk, L, Fredlund, H, Jensen, J S
(2003). Tetracycline treatment does not eradicate Mycoplasma genitalium. Sex. Transm. Infect.
79: 318-319
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»